Brian Bernick
Overview
Explore the profile of Brian Bernick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jensen J, Archer D, Westhoff C, Nelson A, Graham S, Bernick B
J Womens Health (Larchmt)
. 2023 May;
32(7):808-815.
PMID: 37253139
We evaluated satisfaction with use of a segesterone acetate and ethinyl estradiol (0.15/0.013 mg) contraceptive vaginal system (CVS) among women who had recently used a monthly contraceptive vaginal ring or...
2.
Graham S, Archer D, Simon J, Ohleth K, Bernick B
Gynecol Endocrinol
. 2022 Sep;
38(11):891-910.
PMID: 36075250
The objective of the present document was to review/summarize reported outcomes compared between menopausal hormone therapy (MHT) containing estradiol (E2) versus other estrogens and MHT with progesterone (P4) versus progestins...
3.
McClung M, Kagan R, Graham S, Bernick B, Mirkin S, Constantine G
Menopause
. 2022 Feb;
29(3):304-308.
PMID: 35213517
Objective: To evaluate bone turnover markers (BTM) in the REPLENISH trial (NCT01942668). Methods: REPLENISH evaluated oral estradiol/progesterone (E2/P4) for the treatment of moderate to severe vasomotor symptoms (VMS) in postmenopausal...
4.
Mirkin S, Simon J, Liu J, Archer D, Castro P, Graham S, et al.
Menopause
. 2021 May;
28(9):998-1003.
PMID: 34054104
Objective: To evaluate endometrial progesterone receptor (PGR) expression in menopausal women who used vaginal 4-μg and 10-μg estradiol (E2) inserts or placebo. Methods: REJOICE was a randomized, placebo-controlled trial investigating...
5.
Liu J, Plagianos M, Archer D, Simon J, Kaunitz A, Graham S, et al.
Contraception
. 2021 Mar;
104(3):229-234.
PMID: 33785318
Objective: To predict serum segesterone (SA) and ethinyl estradiol (EE) levels after 364 days of hypothetical continuous use (without removal) of a cyclic contraceptive vaginal system (CVS) containing 0.15 mg...
6.
Constantine G, Simon J, Kaunitz A, Pickar J, Revicki D, Graham S, et al.
Menopause
. 2020 Oct;
27(11):1236-1241.
PMID: 33110039
Objective: The aim of the study was to evaluate the clinically meaningful effect of oral TX-001HR (17β-estradiol [E2]/progesterone [P4]) capsules on hot flushes severity (vasomotor symptoms [VMS] severity scale) using...
7.
Black D, Minkin M, Graham S, Bernick B, Mirkin S
Menopause
. 2020 Sep;
28(1):32-39.
PMID: 32932401
Objective: To examine the impact of a single-capsule 17β-estradiol (E2)/progesterone (P4) on weight and blood pressure (BP) when treating moderate to severe vasomotor symptoms in postmenopausal women with a uterus....
8.
Liu J, Bernick B, Mirkin S
Expert Opin Drug Deliv
. 2020 Sep;
17(11):1573-1581.
PMID: 32877254
Introduction: Vulvar and vaginal atrophy (VVA) affects up to two thirds of postmenopausal women, with symptoms of vaginal dryness, dyspareunia, and vulvar/vaginal irritation. Despite the availability of various treatments, women...
9.
Virro J, Besinque K, Carney C, Gross D, Bernick B, Mirkin S
Pharmacy (Basel)
. 2020 Sep;
8(3).
PMID: 32872116
Annovera (segesterone acetate and ethinyl estradiol vaginal system) is a US Food and Drug Administration FDA-approved long-lasting, reversible contraceptive that is fully administered by the user and does not require...
10.
Liu J, Black D, Larkin L, Graham S, Bernick B, Mirkin S
Menopause
. 2020 Aug;
27(12):1388-1395.
PMID: 32842052
Objective: To evaluate the effect of a single-capsule, bioidentical 17β-estradiol (E2) and progesterone (P4) hormone therapy on mammograms and breasts in postmenopausal women after 1 year of use. Methods: In...